The Current Ratio as of September 2024 (TTM) for MannKind Corporation (MNKD) is 4.07

According to MannKind Corporation’s latest financial reports and current stock price. The company's current Current Ratio is 4.07. This represents a change of 17.78% compared to the average of 3.46 of the last 4 quarters.

MannKind Corporation (MNKD) Historical Current Ratio (quarterly & annually)

How has MNKD Current Ratio performed in the past?

The mean historical Current Ratio of MannKind Corporation over the last ten years is 1.70. The current 4.07 Current Ratio has changed 23.87% with respect to the historical average. Over the past ten years (40 quarters), MNKD's Current Ratio was at its highest in in the December 2021 quarter at 4.54. The Current Ratio was at its lowest in in the March 2016 quarter at 0.18.

MannKind Corporation (MNKD) Current Ratio by Quarter and Year

Discovering the peaks and valleys of MannKind Corporation Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

MannKind Corporation (MNKD) Average Current Ratio

How has MNKD Current Ratio performed in the past?

The current Current Ratio of MannKind Corporation (MNKD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

MannKind Corporation (MNKD) Current Ratio vs. Peers

How is MNKD’s Current Ratio compared to its peers?

MannKind Corporation’s Current Ratio is greater than BioMarin Pharmaceutical Inc. (3.05), less than Vaxcyte, Inc. (17.88), less than Liquidia Corporation (6.08), less than Legend Biotech Corporation (4.84), greater than Bio-Techne Corporation (3.87), less than United Therapeutics Corporation (4.35), less than Larimar Therapeutics, Inc. (10.93), less than Day One Biopharmaceuticals, Inc. (4.09), greater than Kiniksa Pharmaceuticals, Ltd. (3.57), greater than Verastem, Inc. (3.28), less than ImmunoGen, Inc. (5.47), less than Immutep Limited (18.25), less than Intercept Pharmaceuticals, Inc. (4.22), less than Elevation Oncology, Inc. (41.10), less than Acer Therapeutics Inc. (0), greater than NRx Pharmaceuticals, Inc. (0.10), greater than Pasithea Therapeutics Corp. (0.21), less than SAB Biotherapeutics, Inc. (6.20), less than MiNK Therapeutics, Inc. (5.24), greater than Affimed N.V. (0.93), greater than Adaptimmune Therapeutics plc (2.71), greater than Sangamo Therapeutics, Inc. (3.09), greater than null (1.03),

Build a custom stock screener for MannKind Corporation (MNKD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MannKind Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MannKind Corporation (MNKD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MannKind Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.